

Reflex

Submission date 04/05/2009	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered
Registration date 30/06/2009	Overall study status Completed	<input checked="" type="checkbox"/> Protocol
Last Edited 18/06/2020	Condition category Mental and Behavioural Disorders	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Prof Andre Aleman

Contact details

Department of Neurosciences
NeuroImaging Centre Groningen
Cognitive Neuropsychiatry
Ant. Deusinglaan 2
Groningen
Netherlands
9713 AW

-

a.aleman@med.umcg.nl

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

ABR 27146

Study information

Scientific Title

Reflex

Study objectives

Current information as of 10/12/09:

The preconditions of poor insight in schizophrenia, self-reflection, idiosyncratic self-certainty and stigma sensitivity, can be improved by a treatment aiming to stimulate perspective taking and to decrease of internalized stigma.

Initial information at time of registration:

Can poor insight with schizophrenia be improved with a treatment aimed at self-reflection and the decrease of internalized stigmata?

Please note that as f 10/12/09 this record has been extensively updated. All updates can be found under the relevant field with the above update date. In addition, please note that the target number of participants has been changed from 80 to 145. The anticipated start and end dates for this trial have been updated from 01/09/2009 and 01/09/2011 to 01/05/2010 and 01/10/2011.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Added 10/12/09:

Approved by the Medical Ethical Testing Committee (METc) UMCG on 13th of October 2009

Study design

Multi-centre randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied

Psychic disorders; schizophrenia and other psychotic disorders

Interventions

Current information as of 10/12/09:

Patients will have 12 one-hour group therapy sessions with a psychologist. The training consists of three modules, each module consists of four group sessions. During these sessions patients are stimulated to reflect upon their own thoughts, behavior and feelings and integrate changes that have occurred during their illness in the self-image. They are constantly encouraged to distinguishing factual information from opinions and to take the perspective of others. The active control condition consists of group wise drill and practice cognitive remediation training. The total duration of the intervention will be 12 hours.

Initial information at time of registration:

Patients will have 16 group therapy sessions with a psychologist. In these sessions, stigmatising beliefs are disputed and self-reflection is stimulated. On a daily basis SMS-messages will be sent to stimulate self-reflection. After a prompt patients are required to fill out a short form with short questions about their cognitions and emotions. Weekly group sessions will be based on the patients' responses.

Control condition: care as usual and additional befriending sessions with a therapist.

The total duration of interventions will be 16 hours. Follow-up assessments will take 3 x 90 minutes.

Added 03/01/2011:

Added to the trial is a fMRI/MRS evaluation for 40 of the 145 patients in the study (20 patients and 20 controls). For the 20 patients the fMRI/MRS will be added before and after the psychosocial intervention/training. Duration: 2x 1 hour.

Intervention Type

Other

Phase

Not Applicable

Primary outcome measure

Current information as of 10/12/09:

Self-reflection, idiosyncratic self-certainty and stigma sensitivity:

1. Beck Cognitive Insight Scale (BCIS)
2. Selfreflection and Insight Scale (Z RIS)
3. Internalised Stigma: Internalized Stigma of Mental Illness Scale (ISMIS)

Initial information at time of registration

Insight, assessed by the following:

1. Beck Cognitive Insight Scale (BCIS)
2. Schedule for the Assessment of Insight - Expanded Version (SAI-E)

Secondary outcome measures

Current information as of 10/12/09:

Depression, symptoms, self-esteem and quality of life:

1. Insight (SAI-E)
2. Depression: Beck Depression Inventory (BDI-II)
3. Symptoms: Positive and Negative Syndrome Scale (PANSS)

4. Self-esteem
5. Quality of life: Manchester Short Assessment of Quality of Life (MANSA)

Initial information at time of registration:

Social functioning, depression, internalised stigma, quality of life and symptoms will be assessed by the following:

1. Community Functioning: Social Functioning Scale
2. Depression: Beck Depression Inventory (BDI-II)
3. Symptoms: Positive and Negative Syndrome Scale (PANSS)
4. Internalised Stigma: Internalized Stigma of Mental Illness Scale (ISMIS)
5. Self-esteem: Self-Esteem Rating Scale (SERS) SF-20 (Dutch version)
6. Quality of life: Manchester Short Assessment of Quality of Life (MANSA)

Overall study start date

01/05/2010

Completion date

01/10/2011

Eligibility

Key inclusion criteria

1. Both males and females, age: 18 years or older
2. A diagnosis of schizophrenia according to Diagnostic And Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria
3. Impaired insight (based on structured assessment) (PI< 9)
4. Internalized stigma (ISMIS items 6+13+17+18 <6)
5. Able to give informed consent

Initial information at time of registration:

1. Both males and females, age between: 18-65
2. A diagnosis of schizophrenia according to Diagnostic And Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) criteria
3. Impaired insight (based on structured assessment)
4. Willing to give written informed consent

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

Added 10/12/09: 145

Total final enrolment

121

Key exclusion criteria

Current information as of 10/12/09:

1. Florid psychosis
2. Co-morbid neurological disorder

Initial information at time of registration:

1. Florid psychosis
2. Patients falling under the BOPZ law, or who are unable to give informed consent according to the Wet op Geneeskundige Behandelovereenkomsten
3. Co-morbid neurological disorder
4. IQ below 75

Date of first enrolment

01/05/2010

Date of final enrolment

01/10/2011

Locations**Countries of recruitment**

Netherlands

Study participating centre**Department of Neurosciences**

Groningen
Netherlands
9713 AW

Sponsor information**Organisation**

University Medical Center Groningen (UMCG) (Netherlands)

Sponsor details

Hanzeplein 1
Groningen
Netherlands
9700 RB

-

a.aleman@med.umcg.nl

Sponsor type

University/education

Website

<http://www.umcg.nl>

ROR

<https://ror.org/03cv38k47>

Funder(s)

Funder type

Research organisation

Funder Name

European Science Foundation/ The Netherlands Organization for Scientific Research (NWO) (Netherlands)

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article	study protocol	05/10/2011		Yes	No
Results article	results	01/04/2019	18/06/2020	Yes	No